Evidence map›Paper›PMID 38036631›Full record

ArticleLeukemia2024

Correction: Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.

Ze Tian, Chunhua Shi, Guojun Yang, Jason K Allen, Qing Shi, Amin Al-Shami, Jill Wardell Olson, Melinda G Smith, Qing Chang, Jasbir Kaur and 10 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Ze TianORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ztian1@mdanderson.org.ORCID http://orcid.org/0009-0009-2637-3378
Chunhua Shi *ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guojun Yang *ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason K Allen *ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qing Shi *ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amin Al-ShamiORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jill Wardell OlsonORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7178-7424
Melinda G SmithORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qing ChangORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jasbir KaurORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Junping YouORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Timothy E LoftonORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michelle A GonzalezORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qi ZhangDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7918-8952
DongXing ZhaORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sarah K TasianDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia; Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-1327-1662
Nitin JainDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Marina Y KonoplevaDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Timothy HeffernanORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. TPHeffernan@mdanderson.org.
Jeffrey J MolldremORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jmolldre@mdanderson.org.ORCID http://orcid.org/0000-0003-1196-1715

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38036631
PMCPMC10776386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.